In the race to bolster pipelines and drive growth, biopharma manufacturers are reexamining traditional practices and reimagining market research protocols. Biopharma business development and licensing ...

The campaign will include patient stories, education resources, and is being held in partnership with the Glaucoma Research Foundation. Bausch + Lomb announced the launch of the second annual Faces of ...

Swoop announced its acquisition of MyHealthTeam, creator of one of the largest opted-in patient social networks in the US. The companies share a vision of making vetted information more available for ...

Mary Kosinski joined the firm as global managing director for the sector, along with other leadership additions. Mary Kosinski is the new global managing director of health and life sciences at ...

Abrysvo and Arexvy will now be required to come with labeling that includes a warning about a potential increased risk of Guillain-Barré Syndrome. The FDA announced that it has mandated updates to the ...

Klick Health announced its acquisition of market access strategy and value communications specialist Peregrine Market Access. This move is part of Klick’s ongoing efforts to build out its life ...

Deloitte’s US life sciences sector leader discusses the trends he believes will have the most impact in 2025. According to a new report from Deloitte, the life sciences industry will have a ...

Breakthrough Therapy Designation for GSK5764227 was based on data from the ARTEMIS-002 Phase II trial, which demonstrated promising efficacy and safety in 42 osteosarcoma patients. The FDA has granted ...

Jennifer Hawks Bland, CEO of NewYorkBIO, shares her journey from litigation to biotech leadership, discusses fostering innovation in New York's thriving bioscience ecosystem, and outlines her vision ...

John Hood, CEO, Endeavor BioMedicines discusses a potential timeline on availability of ENV-101 for patients with IPF and further validation of the treatment's safety profile. PE: Given the ...

Both companies have produced AI-powered technology that improves data collection and analysis. As the pharma industry continues to embrace new technologies, it’s becoming increasingly clear that the ...

Data from the Phase III trial program found that AXS-05 demonstrated statistically significant efficacy in treating Alzheimer disease agitation. Axsome Therapeutics announced the successful completion ...